Over the last two years, big pharma has gotten behind the idea of smartphone-connected inhalers for asthma and COPD in a big way. Two acquisitions, a $3 million investment, and a number of pilot and ...

GlaxoSmithKline and Madison, Wisconsin-based Propeller Health announced a partnership today in which Propeller will develop and manufacture a custom sensor for GSK's Ellipta inhaler for COPD patients.

High-volume production justifies investments in automation—such as robotic valve assembly and inline dose testing—that reduce labor costs, enhance consistency, and optimize yield. Leading suppliers ...

According to the report, the 'respiratory inhaler devices market' was valued at $32.4 billion in 2024, and is estimated to reach $51.9 billion by 2034, growing at a CAGR of 4.8% from 2025 to 2034.The ...

Respiratory inhaler devices are essential tools for delivering medication directly into the lungs for the treatment and management of respiratory conditions such as asthma, chronic obstructive ...